Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 270 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Type 2 on Insulin Clear all
Completed Phase 4 Interventional Results available

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

NCT01774968
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Regular U-500 Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Not applicable Interventional

The Effect of a Low-fat Vegan Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes

NCT06106035
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 in Obese
Interventions
low-fat vegan diet
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Phase 4 Interventional

Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin

NCT00384215
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
insulin glargine [rDNA origin] injection
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Phase 4 Interventional

Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus

NCT04030091
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
3 hours humulin R 100 IU/mL PIT, 2 hours humulin R 100 IU/mL PIT
Drug
Lead sponsor
Sciema UG
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 8, 2026, 1:32 PM EDT
Terminated Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

NCT02131272
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin detemir, Insulin NPH, Diet/exercise
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of the Effects of Vitamin C on Patients With Type 2 Diabetes

NCT00001870
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin Dependent, Non-Insulin Dependent
Interventions
Acetylcholine
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

NCT01814137
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin degludec, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Goodyear, Arizona • Phoenix, Arizona • Anaheim, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

NCT00283751
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
21
States / cities
Greenbrae, California • La Mesa, California • West Palm Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 8, 2026, 1:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

NCT07219602
View directory record Official record
Conditions
Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
Interventions
obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
32
States / cities
Sun City West, Arizona • La Jolla, California • Pomona, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 8, 2026, 1:32 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect Pulsatile IV Insulin Therapy on the Quality of Life in Patients With Types 1 and 2 Diabetes

NCT00228878
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Effects of Pulsatile IV insulin on Diabetic Quality of Life
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus

NCT00237640
View directory record Official record
Conditions
Diabetes Mellitus, Adult Onset
Interventions
Cinnamon or placebo 500 mg capsule twice daily
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 22, 2008 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans

NCT03077360
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Pre-diabetes, Obesity
Interventions
Lifestyle
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin

NCT02033876
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ursodiol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

US Inhaled Insulin Dose Titration Study

NCT00246623
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exubera (inhaled insulin), 8-point glucose diary (to assess pre- and post prandial glucoses), Meal Tolerance Test, 24-hour continuous glucose monitoring (at select sites), Pulmonary Function Testing, Hypoglycemic Event Monitoring, Laboratory Assessments, Nutritional Counseling and Diabetes Education
Drug · Procedure · Behavioral
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2008 · Synced Oct 8, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional

Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics

NCT00330200
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ISIS 113715
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 8, 2026, 1:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Milk Fat Intake and Metabolic Health Markers

NCT02659748
View directory record Official record
Conditions
Insulin Sensitivity, Type 2 Diabetes
Interventions
Milk Fat, Control Fat
Dietary Supplement
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 8, 2026, 1:32 PM EDT
Recruiting Not applicable Interventional

Virtual Diabetes Care for Adults With Type 2 Diabetes on Medicaid and Insulin Therapy

NCT06814184
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
app-based nurse-led virtual diabetes care
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Two Days of Bedrest on Insulin Resistance in Type 2 Diabetics

NCT00508599
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Resistance
Interventions
Study 2 (48 hours of complete bed rest)
Other
Lead sponsor
University of New Mexico
Other
Eligibility
21 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes

NCT01886989
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cocoa polyphenols
Dietary Supplement
Lead sponsor
Arpita Basu
Other
Eligibility
21 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

NCT00634842
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
66
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 8, 2026, 1:32 PM EDT
Recruiting Not applicable Interventional

Peanuts for Cardiometabolic, Brain, and Intestinal Health

NCT06867198
View directory record Official record
Conditions
Prediabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Cognition, Microvascular Function, Gut Microbiota, Endothelial Function (Reactive Hyperemia), Arterial Stiffness, Blood Pressure, Adult
Interventions
Peanuts
Dietary Supplement
Lead sponsor
Georgia State University
Other
Eligibility
20 Years to 59 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

Recombinant Human Leptin Therapy Effects on Insulin Action

NCT01207934
View directory record Official record
Conditions
Type Two Diabetes Mellitus
Interventions
placebo, low-dose leptin, high-dose leptin
Dietary Supplement · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

NCT03021187
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Anniston, Alabama • Birmingham, Alabama • Fountain Hills, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 8, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients

NCT04673656
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
BKR-017
Dietary Supplement
Lead sponsor
BioKier Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Durham, North Carolina • Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 8, 2026, 1:32 PM EDT